Długosz-Danecka M, et al. - Researchers investigated the ability of average relative dose intensity (ARDI) of an anthracycline-containing regimen for predicting diffuse large B-cell lymphoma (DLBCL) outcome independently from the international prognostic index (IPI). Participants included 223 Caucasian DLBCL patients. These participates completed at least four cycles of first-line immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). The investigators used specially developed software to estimate ARDI in each individual patient and assessed chemotherapy prescription also, which instantly revealed all causes of its decrease. The most common cause of decreased ARDI was prolonged intervals between cycles of immunochemotherapy and this was attributed to neutropenia and infections. Findings revealed a significantly better outcome among DLBCL patients with an ARDI > 90%, irrespective of the IPI; therefore, an adequate dose density through efficient neutropenia prophylaxis and cardiac protection was recommended.